Diverse coactivator recruitment through differential PPARγ nuclear receptor agonism

Genetics and Molecular Biology

Volumn 36, Issue 1, 2013, Pages 134-139

  Lizcano, Fernando ^a   Vargas, Diana ^a  

^a UNIVERSIDAD DE LA SABANA   (Colombia)

Author keywords

DNA binding proteins co activator; Gene expression; Telmisartan; Transcription

Indexed keywords

NUCLEAR RECEPTOR COACTIVATOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; STEROID RECEPTOR COACTIVATOR 1; TELMISARTAN;

ADIPOSE TISSUE CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL STRAIN 3T3; CELL STRAIN U2OS; CONTROLLED STUDY; DRUG ACTIVITY; GENETIC TRANSFECTION; PLASMID; WESTERN BLOTTING;

EID: 84874903916     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572013005000002     Document Type: Article

References (25)

1. Amano Y, Yamaguchi T, Ohno K, Niimi T, Orita M, Sakashita H and Takeuchi M (2012) Structural basis for telmisartan-mediated partial activation of PPARγ gamma. Hypertens Res 35:715-719.
2. Aoyagi S and Archer TK (2008) Dynamics of co-activator recruitment and chromatin modifications during nuclear receptor mediated transcription. Mol Cell Endocrinol 280:1-5.
3. Bähr IN, Tretter P, Krüger J, Stark RG, Schimkus J, Unger T, Kappert K, Scholze J, Parhofer KG and Kintscher U (2011) High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptortarget genes in patients with the metabolic syndrome. Hypertension 58:725-732.
4. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Willimas TDM, Lewis H, Schafer AJ, et al. (1999) Dominant negative mutations in human PPARγ gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883.
5. Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C and Galli E (2011) Telmisartan: Just an antihypertensive agent? A literature review. Expert Opin Pharmacother 12:2719-2735.
6. Ferre P (2004) The biology of PPARγ receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1:S43-S50.
7. Gelman L, Feige JN and Desvergne B (2007) Molecular basis of selective PPARgamma modulation for the treatment of type 2 diabetes. Biochim Biophy Acta 1771:1094-1007.
8. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y and Breyer MD (2005) Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absortion. Nat Med 11:861-866.
9. Hong H, Kohli K, Trivedi A, Johnson D and Stallcup M (1996) GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 93:4948-4952.
10. Kintscher U (2012) And in the end - Telmisartan directly binds to PPAR. Hypertens Res 35:704-705.
11. Lago R, Singh P and Nesto R (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 370:1129-1136.
12. Lehrke M and Lazar MA (2005) The many faces of PPAR. Cell 123:993-999.
13. Nissen S and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471.
14. Nolte RT, Wisley GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Wilson TM, Christopher KG and Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferators receptor-gamma. Nature 395:137-143.
15. Onate S, Tsai S, Tsai M and O'Malley B (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357.
16. Rosenfeld M and Glass CK (2001) Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 40:36865-36868.
17. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54:3442-3452.
18. Shulman AI and Mangelsdorf DJ (2005) Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 353:604-615.
19. Staels B and Fruchart JC (2005) Therapeutic roles of peroxisome proliferator activated receptor agonists. Diabetes 54:2460-2470.
20. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A and Naruse M (2009) A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 150:862-870.
21. Takeshita A, Yen P, Ikeda M, Cardona G, Liu Y, Koibuchi N, Norwitz ER and Chin WW (1998) Thyroid hormone response elements differentially modulate the interactions of thyroid hormone receptors with two receptor binding domains in the steroid receptor coactivator-1. J Biol Chem 273:21554-21562.
22. Tontonoz P, Hu E, Graves RA, Budavari AI and Spiegelman BM (1994) mPPARγ gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234.
23. Toyama K, Nakamura T, Kataoka K, Yasuda O, Fukuda M, Tokutomi Y, Dong YF, Ogawa H and Kim-Mitsuyama S (2011) Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor--dependent activity. Biochem Biophys Res Commun 410:508-513.
24. Yamauchi T, Kamon J, Waki H, Murakami K, Matojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, et al. (2001) The mechanism by which both hetetozygous peroxisome proliferator-activated receptor gamma (PPARγ gamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245-41254.
25. Zhu Y, Kan L, Qi C, Kanwar Y, Yeldandi A, Rao M and Reddy J (2000) Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a co-activator for PPAR. J Biol Chem 275:13510-13516.